| Characteristics | Replanning group | Non-replanning group | P-value |
| Number of patients | 11 | 11 |
|
| Age (range) | 76 (44 - 81) | 68 (53 - 83) | 0.41 |
| Sex |
|
| 0.31 |
| Male | 7 | 10 |
|
| Female | 4 | 1 |
|
| BMI (kg/m2) | 24.4 | 22.5 | 0.55 |
| (range) | (17.0 - 28.66) | (15.9 - 28.7) |
|
| Primary tumor site |
|
| 0.32 |
| Nasopharynx | 1 | 3 |
|
| Oropharynx | 3 | 1 |
|
| Hypopharynx | 3 | 2 |
|
| Larynx | 3 | 1 |
|
| Maxillary sinus | 0 | 2 |
|
| Ethmoid sinus | 0 | 1 |
|
| Nasal cavity | 1 | 0 |
|
| Oral tongue | 0 | 1 |
|
| Pathological diagnosis |
|
| 0.33 |
| Squamouscell carcinoma | 11 | 9 |
|
| Undifferentiated carcinoma | 0 | 1 |
|
| Neuroblastoma | 0 | 1 |
|
| Nodal staging |
|
| 1.00 |
| N0 | 3 | 3 |
|
| N1 | 3 | 3 |
|
| N2 | 5 | 5 |
|
| RT |
|
| 0.53 |
| Definitive RT | 9 | 10 |
|
| Postoperative RT | 2 | 1 |
|
| Prescription doses of RT | 70 (60 - 70) Gy | 70 (60 - 70) Gy | 0.17 |
| 70 Gy | 9 | 7 |
|
| 66 Gy | 0 | 3 |
|
| 60 Gy | 2 | 1 |
|
| Chemotherapy |
|
| 0.11 |
| Carboplatin | 1 | 3 |
|
| Docetaxel | 3 | 1 |
|
| Cisplatin | 1 | 3 |
|
| Cetuximab | 4 | 0 |
|
| None | 2 | 4 |
|
| Timing of the rescan from the initiation of RT | |||
| Fractions | 15 (14 - 19) | 15 (13 - 18) | 0.69 |
| Days | 21 (17 - 30) | 20 (17 - 27) | 0.91 |
| BMI at rescan (kg/m2) | 23.1 | 21.3 | 0.78 |
| (range) | (16.5 - 27.9) | (14.4 - 27.3) |
|
| Weight loss from the initiation of RT to the rescan (%) | |||
| (range) | 5.4 (1.7 - 11.2) | 4.1 (−3.2 - 9.2) | 0.19 |